Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 2026

Promega Corporation has introduced an innovative live-cell target engagement platform designed to enhance drug discovery efforts by enabling the analysis of understudied or difficult-to-interrogate proteins directly within live cells. This new technology, revealed at SLAS 2026, addresses a critical gap that has long existed between traditional biochemical assays and cellular assays, particularly for proteins that have been challenging to study due to their complex biology or lack of suitable tools.

The platform, known as TarSee, leverages advanced cellular techniques to provide researchers with the ability to observe how potential drug candidates interact with target proteins in their native cellular environment. This approach contrasts with conventional methods that often rely on isolated proteins or cell lysates, which can fail to capture the full complexity of protein behavior and drug engagement in living systems. By enabling live-cell analysis, Promega's technology offers a more physiologically relevant assessment of target engagement, which is crucial for validating drug candidates and understanding their mechanisms of action.

One of the key advantages of the TarSee platform is its applicability to a broad range of proteins, including those that have historically been considered 'undruggable' or difficult to target due to their structural or functional properties. This capability opens new avenues for drug discovery by expanding the druggable proteome—the subset of proteins that can be modulated by therapeutic agents. Researchers can now investigate these challenging targets with greater confidence, potentially leading to the development of novel therapies for diseases that currently lack effective treatments.

The introduction of this technology also has significant implications for the pharmaceutical and biotechnology industries. By providing a robust and reliable method for live-cell target engagement analysis, Promega's platform can accelerate the drug development pipeline, reduce attrition rates, and improve the selection of promising drug candidates early in the discovery process. This efficiency gain is particularly valuable given the high costs and lengthy timelines traditionally associated with drug development.

Furthermore, the platform's design facilitates integration with existing workflows and instrumentation, making it accessible to a wide range of research laboratories. Its compatibility with live-cell imaging and high-throughput screening techniques means that it can be employed for both detailed mechanistic studies and large-scale compound screening campaigns. This versatility enhances its utility across various stages of drug discovery and development.

In summary, Promega's live-cell target engagement platform represents a significant advancement in the field of drug discovery. By enabling the study of previously intractable proteins in their native cellular context, it expands the potential targets for therapeutic intervention and offers a more accurate assessment of drug-target interactions. This innovation holds promise for accelerating the development of new medicines and addressing unmet medical needs.